{"id":"NCT04019704","sponsor":"Axsome Therapeutics, Inc.","briefTitle":"A Trial of AXS-05 in Patients With Major Depressive Disorder","officialTitle":"AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-20","primaryCompletion":"2019-11-26","completion":"2019-12-05","firstPosted":"2019-07-15","resultsPosted":"2022-10-12","lastUpdate":"2022-10-12"},"enrollment":327,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression","Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"AXS-05","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AXS-05","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).","primaryOutcome":{"measure":"Change in MADRS Total Score From Baseline to Week 6","timeFrame":"6 weeks","effectByArm":[{"arm":"AXS-05","deltaMin":15.91,"sd":0.921},{"arm":"Placebo","deltaMin":12.04,"sd":0.862}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["35649167","34510411"],"seeAlso":["http://www.axsome.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":162},"commonTop":["All Others, occurring in <5% of Subjects","Dizziness","Nausea","Headache","Diarrhea"]}}